Search Results - "van Klaveren, R. J"

Neglectable benefit of searching for incidental findings in the Dutch-Belgian lung cancer screening trial (NELSON) using low-dose multidetector CT by van de Wiel, J C M, Wang, Y, Xu, D M, van der Zaag-Loonen, H J, van der Jagt, E J, van Klaveren, R J, Oudkerk, M

“…The purpose of this study was to prospectively determine the frequency and spectrum of incidental findings (IFs) and their clinical implications in a high risk…”
Get full text

Pre-operative pulmonary evaluation of lung cancer patients: a review of the literature by van Tilburg, P. M. B, Stam, H, Hoogsteden, H. C, van Klaveren, R. J

“…Complete anatomical resection of the primary tumour is still the standard of care in patients with early stage lung cancer. Because these patients are usually…”
Get full text

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma by VAN HAARST, J. M. W, BAAS, P, MANEGOLD, Ch, SCHOUWINK, J. H, BURGERS, J. A, DE BRUIN, H. G, MOOI, W. J, VAN KLAVEREN, R. J, DE JONGE, M. J. A, VAN MEERBEECK, J. P

“…Malignant pleural mesothelioma is a notoriously chemoresistant tumour. However, a recent single institution study showed an impressive activity of gemcitabine…”
Get full text

Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON) by van den Bergh, K A M, Essink-Bot, M L, Borsboom, G J J M, Th Scholten, E, Prokop, M, de Koning, H J, van Klaveren, R J

“…Background: In lung cancer CT screening, participants often have an indeterminate screening result at baseline requiring a follow-up CT. In subjects with…”
Get full text

Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial by VAN DEN BERGH, K. A. M, ESSINK-BOT, M. L, BORSBOOM, G. J. J. M, SCHOLTEN, E. T, KLAVEREN, R. J,van, DE KONING, H. J

“…The long-term effects of lung cancer computed tomography (CT) screening on health-related quality of life (HRQoL) have not yet been investigated. In the…”
Get full text

The impact of a lung cancer computed tomography screening result on smoking abstinence by VAN DER AALST, C. M, VAN KLAVEREN, R. J, VAN DEN BERGH, K. A. M, WILLEMSEN, M. C, DE KONING, H. J

“…Receiving a lung cancer computed tomography screening result might be a teachable moment for smoking cessation, but it might also unintentionally reassure…”
Get full text

Informed participation in a randomised controlled trial of computed tomography screening for lung cancer by van den Bergh, K. A. M, Essink-Bot, M. L, van Klaveren, R. J, de Koning, H. J

“…The actual lung cancer (screening) knowledge, attitudes, risk perceptions, reasons to participate in or decline participation, and informed decisions of…”
Get full text

Association of the transfer coefficient of the lung for carbon monoxide with emphysema progression in male smokers by MOHAMED HOESEIN, F. A. A, ZANEN, P, VAN GINNEKEN, B, VAN KLAVEREN, R. J, LAMMERS, J-W. J

“…A decreased transfer coefficient of the lung for carbon monoxide (K(CO)) is associated with emphysema. We evaluated whether in heavy smokers, baseline K(CO)…”
Get full text

Lung cancer screening by low-dose spiral computed tomography by van Klaveren, R.J, Habbema, J.D.F, Pedersen, J.H, de Koning, H.J, Oudkerk, M, Hoogsteden, H.C

“…The poor prognosis of lung cancer has barely changed in the last decades, but the prognosis is better when the disease is detected earlier. Lung cancer…”
Get full text

Blinded and uniform cause of death verification in a lung cancer CT screening trial by Horeweg, N, van Klaveren, R.J, Groen, H.J.M, Lammers, J.-W.J, Weenink, C, Nackaerts, K, Mali, W, Oudkerk, M, de Koning, H.J

“…Abstract Disease-specific mortality is the final outcome of a lung cancer screening trial, therefore cause of death verification is crucial. The use of death…”
Get full text

Generalisability of the results of the Dutch–Belgian randomised controlled lung cancer CT screening trial (NELSON): Does self-selection play a role? by van der Aalst, C.M, van Iersel, C.A, van Klaveren, R.J, Frenken, F.J.M, Fracheboud, J, Otto, S.J, de Jong, P.A, Oudkerk, M, de Koning, H.J

“…Abstract The degree of self-selection in the Dutch–Belgian randomised controlled lung cancer screening trial (NELSON) was determined to assess the…”
Get full text

Cellular glutathione turnover in vitro, with emphasis on type II pneumocytes by van Klaveren, RJ, Demedts, M, Nemery, B

“…The most important extracellular antioxidant in the lung is glutathione (GSH). The epithelial lining fluid of normal lungs contains very high concentrations of…”
Get full text

Nitric oxide diffusing capacity versus spirometry in the early diagnosis of emphysema in smokers by van der Lee, I, Gietema, H.A, Zanen, P, van Klaveren, R.J, Prokop, M, Lammers, J.-W.J, van den Bosch, J.M.M

“…Summary The diffusion capacity for nitric oxide (DLNO) is independent of pulmonary capillary blood volume and equals the membrane diffusing capacity. Therefore…”
Get full text

A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma by van Meerbeeck, J.P., Baas, P., Debruyne, C., Smit, E.F., van Klaveren, R.J., Galdermans, D., Lentz, M.A., Manegold, C., Giaccone, G.

“…The aim of this study was to investigate the anti-tumour activity of temozolomide in patients with malignant pleural mesothelioma. 27 chemotherapy-naı̈ve…”
Get full text

Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: Results from 2 phase I studies by Surmont, V, Smit, E.F, de Jonge, M, Aerts, J.G, Nackaerts, K, Vernhout, R, Gras, J, Van Wijk, A, Phernambucq, E.C.J, van Meerbeeck, J.P, Senan, S, Kraaij, C.J, Chouaki, N, Praag, J, van Klaveren, R.J

“…Abstract Background The objectives were to determine the maximum tolerated dose (MTD) of pemetrexed and cisplatin with concurrent radiotherapy. Secondary…”
Get full text

Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study by Surmont, V., Aerts, Joachim G. J. V., Tan, K. Y., Schramel, F., Vernhout, R., Hoogsteden, Henk C., van Klaveren, R. J.

“…Background. sequential chemotherapy can maintain dose intensity and preclude cumulative toxicity by increasing drug diversity. Purpose. to investigate the…”
Get full text

Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: A non-randomized phase II study by Surmont, V, Aerts, J.G, Pouw, E, Tan, K.Y, Vernhout, R, Gras, J, Salomé, J, Pronk, T, Schmitz, P.I.M, Hoogsteden, H, van Klaveren, R.J

“…Abstract Background Oral treatment regimens with few side effects are appealing in the 2nd or 3rd line treatment of non-small cell lung cancer (NSCLC)…”
Get full text

Increase in γ-Glutamyltransferase by Glutathione Depletion in Rat Type II Pneumocytes by van Klaveren, Rob J, Hoet, Peter H.M, Pype, Jan L, Demedts, Maurits, Nemery, Benoit

“…The purpose of our study was to investigate the effect of oxidative stress or intracellular glutathione (GSH) depletion on γ-glutamyltransferase ( γ-GT)…”
Get full text

A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer by Surmont, V, Aerts, J G J V, van Klaveren, R J, Tournoy, K, Tan, K Y, Vernhout, R M, Schmitz, P I M, Legrand, C, Hoogsteden, H C, van Meerbeeck, J P

“…Carboplatin area under the curve (AUC) 5 ml/min on day 1 with gemcitabine 1,250 mg/m(2) on day 1 and day 8 is a widely used regimen in advanced non-small cell…”
Get more information

Complications following lung surgery in the Dutch-Belgian randomized lung cancer screening trial by van't Westeinde, Susan C., Horeweg, Nanda, De Leyn, Paul, Groen, Harry J.M., Lammers, Jan-Willem J., Weenink, Carla, Nackaerts, Kristiaan, van Klaveren, Rob J.

“…OBJECTIVES To assess the complication rate in participants of the screen arm of the NELSON lung cancer screening trial who underwent surgical resection and to…”
Get full text